Kevin Dunleavy is a Staff Writer at Herald-Mail Media. He focuses on themes related to medicine and healthcare, alternative medicine, and legal affairs, often exploring topics such as the FDA, business leaders, and the impact of lawsuits, particularly in the context of the pharmaceutical industry and wellness. Kevin's work has been featured in prominent outlets including Yahoo Sports, Biotech, NewsBreak, Fierce Pharma, and Deadspin.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kevin Dunleavy's coverage revolves around the healthcare and pharmaceutical industry, focusing on regulatory approvals, drug development, M&A activities, and legal settlements. His articles often cite data and press releases to support the information presented.
Given his focus on regulatory approvals and drug developments, Kevin may be interested in receiving pitches related to new drugs or treatments entering clinical trials or seeking FDA approval. Additionally, he might be interested in insights from experts who can provide analysis of pharmaceutical market trends supported by relevant data.
As Kevin's geographic focus is not specified but given the international nature of pharmaceutical companies' operations and regulations, sources with a global perspective on healthcare and pharmaceuticals are likely to resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Zoey Becker, Kevin Dunleavy, Eric Sagonowsky, Fraiser Kansteiner, Angus Liu
The first day of the J.P. Morgan Healthcare Conference is in the books, featuring high-profile deal announcements from Johnson & Johnson, Eli Lilly, GSK and several other biopharma players.
By: Kevin Dunleavy
After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company's deep pipeline Monday at the J.P.
By: Kevin Dunleavy
The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy Jr. to run the Department of Health and Human Services.
By: Kevin Dunleavy
After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it attempts to reestablish its unique role as a drug developer combating urgent public health threats.
By: Kevin Dunleavy
After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of
By: Kevin Dunleavy
A government watchdog examining the FDA's accelerated approval pathway has released a 32-page report (PDF) that concludes the agency's controversial
By: Kevin Dunleavy
The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took another zig on Thursday
By: Kevin Dunleavy
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk's semaglutide for heart disease and Eli Lilly's tirzepatide for sleep apnea.
By: Kevin Dunleavy
Already on its way to becoming a blockbuster drug, Johnson & Johnson's Spravato has received another potential boost as the FDA has
By: Kevin Dunleavy
After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, including Lonza,
(833) 317-6278 
